Arbutus Biopharma 미래 성장
Future 기준 확인 2/6
Arbutus Biopharma은 연간 수입과 매출이 각각 11.7%와 44.2% 증가할 것으로 예상되고 EPS는 연간 14.5%만큼 증가할 것으로 예상됩니다.
주요 정보
11.7%
수익 성장률
14.5%
EPS 성장률
| Biotechs 수익 성장 | 28.3% |
| 매출 성장률 | 44.2% |
| 향후 자기자본 수익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 20 Nov 2024 |
최근 미래 성장 업데이트
Recent updates
Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity
Jul 05Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up
May 23
Moderna Investors Should Beware Patent-Dispute Fallout
Apr 23Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Apr 10Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 03Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
Nov 09Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio
Oct 24We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher
Nov 11We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'
Sep 12Arbutus stock rises on US patent linked to hepatitis B therapy AB-729
Aug 30Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Aug 06Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Jul 20Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Jun 29We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic
May 11Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues
Mar 08Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Mar 07Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
Dec 17Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov 20Arbutus Biopharma: A First Assessment
Sep 15We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
Jun 29수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2026 | 8 | -81 | N/A | N/A | 1 |
| 12/31/2025 | 5 | -69 | N/A | N/A | 5 |
| 12/31/2024 | 6 | -73 | N/A | N/A | 5 |
| 9/30/2024 | 7 | -77 | -72 | -72 | N/A |
| 6/30/2024 | 10 | -77 | -73 | -73 | N/A |
| 3/31/2024 | 13 | -74 | -79 | -78 | N/A |
| 12/31/2023 | 18 | -73 | -87 | -86 | N/A |
| 9/30/2023 | 22 | -75 | -87 | -86 | N/A |
| 6/30/2023 | 24 | -73 | -84 | -83 | N/A |
| 3/31/2023 | 33 | -70 | -84 | -83 | N/A |
| 12/31/2022 | 39 | -69 | -36 | -35 | N/A |
| 9/30/2022 | 36 | -69 | -38 | -38 | N/A |
| 6/30/2022 | 33 | -76 | -36 | -35 | N/A |
| 3/31/2022 | 21 | -85 | -30 | -29 | N/A |
| 12/31/2021 | 11 | -88 | -68 | -68 | N/A |
| 9/30/2021 | 10 | -87 | -64 | -63 | N/A |
| 6/30/2021 | 8 | -84 | -60 | -59 | N/A |
| 3/31/2021 | 8 | -79 | -54 | -54 | N/A |
| 12/31/2020 | 7 | -76 | -52 | -51 | N/A |
| 9/30/2020 | 6 | -83 | -50 | -50 | N/A |
| 6/30/2020 | 8 | -147 | -61 | -61 | N/A |
| 3/31/2020 | 7 | -156 | -70 | -70 | N/A |
| 12/31/2019 | 6 | -165 | -72 | -71 | N/A |
| 9/30/2019 | 6 | -158 | -75 | -75 | N/A |
| 6/30/2019 | 5 | -100 | -65 | -64 | N/A |
| 3/31/2019 | 5 | -73 | -65 | -64 | N/A |
| 12/31/2018 | 6 | -67 | -69 | -68 | N/A |
| 9/30/2018 | 7 | -83 | -62 | -61 | N/A |
| 6/30/2018 | 12 | -68 | N/A | -64 | N/A |
| 3/31/2018 | 12 | -86 | N/A | -51 | N/A |
| 12/31/2017 | 11 | -85 | N/A | -49 | N/A |
| 9/30/2017 | 8 | -267 | N/A | -53 | N/A |
| 6/30/2017 | 2 | -275 | N/A | -52 | N/A |
| 3/31/2017 | 1 | -387 | N/A | -64 | N/A |
| 12/31/2016 | 1 | -384 | N/A | -58 | N/A |
| 9/30/2016 | 14 | -171 | N/A | -60 | N/A |
| 6/30/2016 | 18 | -180 | N/A | -47 | N/A |
| 3/31/2016 | 21 | -65 | N/A | -48 | N/A |
| 12/31/2015 | 23 | -63 | N/A | -56 | N/A |
| 9/30/2015 | 17 | -62 | N/A | -45 | N/A |
| 6/30/2015 | 17 | -42 | N/A | -49 | N/A |
| 3/31/2015 | 15 | -33 | N/A | -39 | N/A |
| 12/31/2014 | 15 | -39 | N/A | -12 | N/A |
| 9/30/2014 | 18 | -35 | N/A | -3 | N/A |
| 6/30/2014 | 17 | -33 | N/A | 0 | N/A |
| 3/31/2014 | 18 | -30 | N/A | 5 | N/A |
| 12/31/2013 | 15 | -14 | N/A | -7 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: ABUS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: ABUS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: ABUS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: ABUS 의 수익(연간 44.2% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).
고성장 수익: ABUS 의 수익(연간 44.2% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: ABUS 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.